Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals has announced a $7.2 billion acquisition of GW Pharmaceuticals, valuing the company at $220 per American Depositary Share. The deal includes $200 in cash and $20 in Jazz shares, representing a premium of 50% over GW's recent stock price. Expected to close in Q2 2021, this acquisition aims to enhance Jazz's neuroscience portfolio with GW's lead product, Epidiolex, a treatment for severe epilepsy. The combined entity is projected to accelerate revenue growth, driven by a robust pipeline of 19 clinical programs focused on critical unmet patient needs.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will webcast its corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. EST. CEO Bruce Cozadd will provide a business and financial update. The live audio webcast can be accessed on the Jazz Pharmaceuticals website and will be archived for at least a week afterward. The company focuses on developing life-changing medicines in neuroscience and oncology, and operates globally, serving patients in over 90 countries.
Jazz Pharmaceuticals has initiated the submission of a Biologics License Application (BLA) to the FDA for JZP-458, targeting acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in patients with hypersensitivity to E. coli-derived asparaginase. The BLA will be reviewed under the FDA's Real-Time Oncology Review program to expedite approval. JZP-458, a recombinant Erwinia asparaginase, received Fast Track designation in October 2019. The company anticipates launching JZP-458 by mid-2021, addressing significant patient needs.
Jazz Pharmaceuticals, in partnership with PharmaMar, announced results from the ATLANTIS Phase 3 study assessing Zepzelca™ (lurbinectedin) combined with doxorubicin for small cell lung cancer (SCLC) patients who progressed after platinum treatment. While the primary endpoint of overall survival was not met, key secondary analyses favored the combination. The study's safety profile was consistent with known data, showing favorable tolerability. The FDA has already granted accelerated approval for Zepzelca. Next steps include providing ATLANTIS data to the FDA for potential full approval.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the appointment of Jennifer Cook and Mark D. Smith, M.D. to its Board of Directors, effective December 1, 2020. Cook brings over 30 years of biopharmaceutical experience, while Smith is a recognized expert in health policy. The additions aim to enhance Jazz's strategy for transformative growth, leveraging their expertise to advance product development. Meanwhile, board members Elmar Schnee and Paul Berns will step down before the 2021 annual meeting. Jazz has launched three new products this year, indicating strong commercial activity.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 1:10 p.m. EST. Daniel Swisher, President and COO, will provide a company overview and financial update. Interested parties can access the live audio webcast through the Jazz Pharmaceuticals website, where an archive will be available for one week post-event. The company focuses on developing innovative medicines for serious diseases in neuroscience and oncology, serving patients across more than 90 countries.
Jazz Pharmaceuticals announced the presentation of 11 company-sponsored abstracts and several others at the 62nd ASH Annual Meeting from December 5-8, 2020. This record number of accepted abstracts underscores Jazz's commitment to research in hematology and oncology. Highlights include five-year results from the Phase 3 study of Vyxeos in older adults with high-risk acute myeloid leukemia (AML) and data on Defitelio for veno-occlusive disease. The virtual event reflects the company's dedication to addressing urgent therapeutic needs in blood cancers.
Jazz Pharmaceuticals (JAZZ) reported strong third-quarter 2020 results, with total revenues of $600.9 million, a 12% increase from the previous year. The launch of Zepzelca contributed $36.9 million in sales, significantly driving growth in the oncology segment. GAAP net income rose to $148.2 million, or $2.64 per share, while adjusted EPS increased to $4.31. The company raised its 2020 financial guidance, anticipating total revenues of $2.320 - $2.380 billion. Key product launches and R&D progress, including FDA approval of Xywav, highlight a positive trajectory despite COVID-19 challenges.
Jazz Pharmaceuticals announced the publication of a Phase 3 study on Xywav, an oral solution for treating cataplexy and excessive daytime sleepiness in narcolepsy patients. The study demonstrated statistically significant improvements (p0.0001) in the frequency of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo. Xywav has FDA approval and features a formulation with 92% less sodium than traditional treatments. Jazz plans to launch Xywav in Q4 2020, enhancing treatment options for narcolepsy patients.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will host a webcast on October 26, 2020, at 4:30 p.m. EDT to discuss the commercial launch of Xywav™, approved by the FDA on July 21, 2020 for narcolepsy treatment. The solution will be available in early November. The presentation will include insights on sodium intake's effects on cardiovascular health and the evaluation of Xywav for idiopathic hypersomnia. The webcast can be accessed through Jazz Pharmaceuticals' website.